(Q30419228)

English

Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma (English)

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

follicular lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Richard G Ghalie

object named as

Richard G Ghalie

9

0 references

object named as

Paul Hamlin

12

0 references

Benjamin Djulbegovic

5

object named as

Benjamin Djulbegovic

1 reference

Europe PubMed Central

16 August 2017

PMC publication ID

Sattva S Neelapu

2

object named as

Sattva S Neelapu

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

author name string

Arnold Freedman

1

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Craig Nichols

3

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Michael J Robertson

4

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Jane N Winter

6

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

John F Bender

7

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Daniel P Gold

8

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Morgan E Stewart

10

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Vanessa Esquibel

11

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

language of work or name

0 references

publication date

4 May 2009

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

27

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

18

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

3036-3043

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646306

20 June 2018

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646306

20 June 2018

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646306

20 June 2018

Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646306

20 June 2018

Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646306

20 June 2018

Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646306

26 November 2018

Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646306

26 November 2018

Follicular lymphoma international prognostic index.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646306

26 November 2018

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646306

26 November 2018

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646306

26 November 2018

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646306

26 November 2018

Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses

1 reference

https://pubmed.ncbi.nlm.nih.gov/19414675

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19414675

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2008.19.8903

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30419228&oldid=1561115950"